150 related articles for article (PubMed ID: 31619463)
1. On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Morschhauser F; Machiels JP; Salles G; Rottey S; Rule SAJ; Cunningham D; Peyrade F; Fruchart C; Arkenau HT; Genvresse I; Liu L; Köchert K; Shen K; Kneip C; Peña CE; Grevel J; Zhang J; Cisternas G; Reschke S; Granvil C; Awada A
Mol Cancer Ther; 2020 Feb; 19(2):468-478. PubMed ID: 31619463
[TBL] [Abstract][Full Text] [Related]
2. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Patnaik A; Appleman LJ; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Weiss GJ; Sachdev JC; Chadha M; Fulk M; Ejadi S; Mountz JM; Lotze MT; Toledo FG; Chu E; Jeffers M; Peña C; Xia C; Reif S; Genvresse I; Ramanathan RK
Ann Oncol; 2016 Oct; 27(10):1928-40. PubMed ID: 27672108
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL
Ann Oncol; 2017 Sep; 28(9):2169-2178. PubMed ID: 28633365
[TBL] [Abstract][Full Text] [Related]
4. A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
Doi T; Fuse N; Yoshino T; Kojima T; Bando H; Miyamoto H; Kaneko M; Osada M; Ohtsu A
Cancer Chemother Pharmacol; 2017 Jan; 79(1):89-98. PubMed ID: 27915408
[TBL] [Abstract][Full Text] [Related]
5. Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
Munoz J; Follows GA; Nastoupil LJ
Target Oncol; 2021 May; 16(3):295-308. PubMed ID: 33687623
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows GA; Lenz G; Kim WS; Nagler A; Panayiotidis P; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Giurescu M; Cupit L; Liu L; Köchert K; Seidel H; Peña C; Yin S; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL
J Clin Oncol; 2017 Dec; 35(35):3898-3905. PubMed ID: 28976790
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Matasar MJ; Dreyling M; Leppä S; Santoro A; Pedersen M; Buvaylo V; Fletcher M; Childs BH; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e886-e894. PubMed ID: 34389273
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows G; Lenz G; Kim WS; Nagler A; Dimou M; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Munoz J; Rodrigues L; Hiemeyer F; Miriyala A; Garcia-Vargas J; Childs BH; Zinzani PL
Am J Hematol; 2020 Apr; 95(4):362-371. PubMed ID: 31868245
[TBL] [Abstract][Full Text] [Related]
9. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Eltantawy A; Vallejos X; Sebea E; Evans K
Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
[No Abstract] [Full Text] [Related]
10. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
[TBL] [Abstract][Full Text] [Related]
11. Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
Kumar A; Bhatia R; Chawla P; Anghore D; Saini V; Rawal RK
Anticancer Agents Med Chem; 2020; 20(10):1158-1172. PubMed ID: 32183683
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
13. A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
Liu W; Ping L; Xie Y; Sun Y; Du T; Niu Y; Cisternas G; Huang F; Garcia-Vargas J; Childs BH; Mehra A; Reschke S; Wang X; Song Y; Zhu J
Cancer Chemother Pharmacol; 2022 Jun; 89(6):825-831. PubMed ID: 35322287
[TBL] [Abstract][Full Text] [Related]
14. Copanlisib in the treatment of non-Hodgkin lymphoma.
Narkhede M; Cheson BD
Future Oncol; 2020 Sep; 16(26):1947-1955. PubMed ID: 32658557
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Panayiotidis P; Follows GA; Mollica L; Nagler A; Özcan M; Santoro A; Stevens D; Trevarthen D; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL; Dreyling M
Blood Adv; 2021 Feb; 5(3):823-828. PubMed ID: 33560394
[TBL] [Abstract][Full Text] [Related]
16. Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Cheson BD; O'Brien S; Ewer MS; Goncalves MD; Farooki A; Lenz G; Yu A; Fisher RI; Zinzani PL; Dreyling M
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):135-141. PubMed ID: 30584024
[TBL] [Abstract][Full Text] [Related]
17. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
[TBL] [Abstract][Full Text] [Related]
18. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
20. Copanlisib: First Global Approval.
Markham A
Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]